Opioid toxicity is a life-threatening emergency characterized by the classic triad of respiratory depression, CNS depression, and miosis, progressing to respiratory arrest and cardiac arrest if untreated. [1-2] The mainstay of care is early recognition, airway management, ventilatory support, and naloxone administration. [1][3]
1. History
- What substance was used? (heroin, fentanyl, prescription opioids, methadone, extended-release formulations) — critical for predicting duration of toxicity and resedation risk [2][4]
- Route of administration (IV, intranasal, oral, transdermal patch, smoking)
- Time of last use and estimated amount
- Coingestants — alcohol, benzodiazepines, gabapentinoids, stimulants; most opioid deaths involve additional substances [1][4]
- Intentional vs. unintentional — suicidal intent changes disposition
- Tolerance status — opioid-naïve patients are at much higher risk at lower doses
- Prior overdose history and prior naloxone use
- Recent period of abstinence (incarceration, detox, hospitalization) — loss of tolerance is a major risk factor
2. Alarm Features
- Respiratory rate <12/min or apnea [2]
- Cyanosis (lips, fingers)
- Unresponsiveness to verbal/physical stimuli
- Atypical snoring/gurgling — suggests airway obstruction [5-6]
- Cardiac arrest — pulselessness, asystole/PEA
- Pulmonary edema — can develop acutely or after naloxone reversal [2][4]
- "Wooden chest syndrome" — thoracic/diaphragmatic rigidity seen with fentanyl analogs, nearly fatal without expert airway management [7-8]
- Hypothermia — prolonged unresponsive state in cool environment [2]
- Mydriasis in the setting of suspected opioid use suggests severe hypoxia [5-6]
- No response after 10 mg IV naloxone — question the diagnosis of opioid toxicity [9-10]
3. Medications
Antidote
- Naloxone — first-line opioid antagonist [1][3]
- IV: 0.4–2 mg, repeat every 2–3 min as needed [9]
- IN: 2–4 mg, repeat after 3 min [3]
- IM: 0.4 mg, repeat after 3 min [3]
- Goal: restore RR ≥10/min while minimizing precipitated withdrawal [3]
- In opioid-dependent patients, titrate with smaller doses (0.04–0.1 mg IV) to avoid severe withdrawal [9-10]
- Nalmefene — longer-acting alternative, available by prescription only [1]
- Naloxone infusion — 2 mg in 500 mL NS (0.004 mg/mL); titrate to respiratory rate; indicated for recurrent respiratory depression or long-acting opioid ingestion [2][9]
Medications contributing to toxicity
- Benzodiazepines, alcohol, gabapentinoids, muscle relaxants, sedative-hypnotics — potentiate respiratory depression and are NOT reversed by naloxone [4][11]
- CYP3A4 inhibitors (azole antifungals, macrolides, protease inhibitors) — increase opioid levels
- MAOIs — risk of serotonin syndrome with certain opioids (meperidine, tramadol) [12]
Cautions
- High-dose naloxone (8 mg IN) is associated with more severe precipitated withdrawal without survival benefit over 4 mg [3]
- Naloxone duration (30–90 min) is shorter than most opioids — resedation risk is real [1][4]
4. Diet
- NPO if altered mental status or risk of aspiration
- No specific dietary triggers; however, alcohol coingestion is extremely common and worsens respiratory depression
- Post-recovery: hydration and nutritional support, especially in patients with opioid use disorder and malnutrition
5. Review of Systems
- Neuro: level of consciousness, last known normal, seizure activity
- Respiratory: breathing rate, snoring, dyspnea, cough (pulmonary edema)
- Cardiac: chest pain, palpitations (arrhythmia from hypoxia or coingestants)
- GI: nausea/vomiting (aspiration risk), constipation (chronic use)
- Psych: suicidal ideation, depression, substance use history
- MSK: muscle rigidity (fentanyl-related wooden chest) [7-8]
- Skin: track marks, fentanyl patches, abscesses
6. Collateral History and Family History
- Collateral from EMS, bystanders, family is critical — patients are often unresponsive; ask about drug paraphernalia, pill bottles, patches found at scene [13]
- Pharmacy records/PDMP — check for prescribed opioids, benzodiazepines, and other sedatives
- Family history of substance use disorder, psychiatric illness
- Social context: housing instability, incarceration history, recent discharge from treatment program (loss of tolerance)
7. Risk Factors
- High morphine milligram equivalents (MME) — strongest predictor of overdose [14]
- Polysubstance use — especially opioid + benzodiazepine or opioid + alcohol [1][4]
- Recent abstinence/loss of tolerance (post-incarceration, post-detox, post-hospitalization)
- Using alone without a monitor or naloxone available [3]
- Illicit fentanyl exposure — unpredictable potency, narrow therapeutic index [15-16]
- Opioid-naïve patients prescribed opioids
- Comorbidities: COPD, OSA, obesity, hepatic/renal impairment, older age
- Mental health disorders: depression, PTSD, prior suicide attempts
- History of prior overdose
8. Differential Diagnosis
- Benzodiazepine/sedative-hypnotic overdose — similar CNS depression but typically without miosis; no response to naloxone [11]
- Alcohol intoxication — odor of alcohol, no miosis, no naloxone response [11]
- Hypoglycemia — check point-of-care glucose immediately
- Stroke/intracranial hemorrhage — focal neurologic deficits, asymmetric findings
- Postictal state — history of seizure, tongue bite, incontinence
- Carbon monoxide poisoning — environmental exposure, cherry-red skin [17]
- Sepsis/meningitis — fever, hemodynamic instability
- Hypothermia — environmental exposure
- Mixed overdose (most common real-world scenario) — partial naloxone response suggests coingestants [4][11]
Pearl: Absence of miosis does NOT rule out opioid toxicity — meperidine, tramadol, propoxyphene, and severe hypoxia can cause mydriasis. [2]
9. Past Medical History
- Prior overdose episodes and naloxone use
- Opioid use disorder — duration, treatment history (methadone, buprenorphine)
- Chronic pain conditions and current opioid prescriptions
- Psychiatric history (depression, suicidality)
- Hepatic/renal disease (impaired opioid metabolism)
- Pulmonary disease (COPD, OSA — lower threshold for respiratory failure)
- Prior intubations
10. Physical Exam
Vital signs
- Respiratory rate <12/min — hallmark finding [2]
- Bradycardia, hypotension
- Hypothermia
- SpO₂ — may be falsely reassuring on supplemental O₂; monitor respiratory rate and ETCO₂
Focused exam
- Pupils: pinpoint miosis (classic); mydriasis if severe hypoxia [2][5]
- Airway: patency, secretions, snoring, vomitus
- Lungs: crackles (pulmonary edema), decreased breath sounds
- Chest wall: rigidity (wooden chest — fentanyl analogs) [7-8]
- Skin: cyanosis, cold/clammy, track marks, transdermal patches (check axillae, perineum, scrotum, oropharynx) [2]
- Neuro: GCS, response to stimuli, muscle tone (flaccidity vs. rigidity)
11. Lab Studies
- Point-of-care glucose — rule out hypoglycemia immediately
- ABG/VBG — respiratory acidosis (↑ pCO₂), hypoxemia
- Basic metabolic panel — electrolytes, renal function
- Lactate — if concern for shock or prolonged hypoxia
- Urine drug screen — note: standard immunoassays often do NOT detect fentanyl; many false positives/negatives with synthetic opioids [15]
- Serum acetaminophen and salicylate levels — rule out coingestion in all overdoses
- Ethanol level
- CK — if prolonged immobilization (rhabdomyolysis risk)
- Troponin — if concern for hypoxic cardiac injury
- Hepatic panel — if acetaminophen coingestion suspected
12. Imaging
- Chest X-ray — if concern for aspiration pneumonia or pulmonary edema [2]
- CT head — if altered mental status does not improve with naloxone, or if focal neurologic findings suggest stroke/hemorrhage
- Imaging is often unnecessary in straightforward opioid toxicity that responds to naloxone
13. Special Tests
- Capnography (ETCO₂) — superior to pulse oximetry for detecting hypoventilation; should be used for monitoring in the ED and during observation [18]
- Fentanyl-specific immunoassay — if available; standard UDS misses most synthetic opioids [15]
- Poison center consultation — recommended for unknown ingestions or refractory cases [13]
- Body packing evaluation — abdominal X-ray or CT if suspected body stuffing/packing (drug mules)
14. ECG
- Obtain ECG in all overdose patients, especially with unknown coingestants [13]
- QTc prolongation — methadone is a well-known cause; risk of torsades de pointes
- Bradycardia — expected with opioid toxicity
- Wide QRS — suggests coingestant (e.g., tricyclic antidepressant, sodium channel blocker)
- ST changes — hypoxic myocardial injury
15. Assessment
Opioid toxicity presents on a spectrum from mild CNS depression with normal respirations to respiratory arrest and cardiac arrest. [1-2] Key clinical pearls:
- The sine qua non is respiratory depression — a RR ≤12 with miosis and altered consciousness is highly suggestive [2]
- Most deaths involve polysubstance use, making pure opioid toxicity less common than mixed presentations [1][4]
- Fentanyl-related toxicity may present with rapid onset, wooden chest rigidity, and may require higher or repeated naloxone doses [7-8][15]
- Toxic leukoencephalopathy can present hours to weeks after apparent recovery from opioid overdose [5-6]
- Severity stratification: mild (drowsy, RR >12) → moderate (obtunded, RR 8–12) → severe (apneic, cyanotic, pulseless)
16. Treatment Plan
Initial stabilization (ABCs first — always before naloxone): [1]
- Open airway — head-tilt/chin-lift, jaw thrust, suction secretions
- Ventilate — BVM with supplemental O₂; this alone may prevent cardiac arrest
- Administer naloxone — titrate to respiratory rate ≥10/min: [3][9]
- If no response after 10 mg IV naloxone — reconsider diagnosis [9-10]
- Intubation — if naloxone fails, wooden chest syndrome, or severe pulmonary edema [2]
- CPR — for cardiac arrest; prioritize high-quality compressions over naloxone [1]
Post-reversal management
- Monitor for resedation — recurrent respiratory depression occurs in up to 72% of patients treated with titrated low-dose IV naloxone [1]
- Naloxone infusion for long-acting opioid ingestions (methadone, extended-release formulations) [2][4]
- Search for and remove fentanyl patches — check axillae, perineum, scrotum, oropharynx [2]
- Treat pulmonary edema with positive pressure ventilation [4]
- Activated charcoal — only if oral ingestion within 1 hour AND protected airway [2]
Secondary prevention
- Prescribe take-home naloxone at discharge [3]
- Offer initiation of buprenorphine for opioid use disorder from the ED [19]
- Safety planning discussion with patient and supports [3]
17. Disposition
Admit/ICU criteria: [2]
- Ingestion of long-acting or extended-release opioid formulations
- Recurrent respiratory depression requiring naloxone infusion
- Required intubation
- Significant pulmonary edema
- Cardiac arrest survivors
- Intentional overdose (psychiatric hold)
- Significant coingestant requiring monitoring
Observation/discharge criteria: [1][4][20]
- For short-acting opioids (heroin, fentanyl): a minimum 1-hour observation after last naloxone dose may be sufficient if the patient ambulates normally, has normal vital signs, GCS 15, and no evidence of coingestants [20]
- For long-acting opioids: observe 4–6 hours minimum after last naloxone dose; longer if on infusion [2]
- Patients who received prehospital naloxone and refuse transport: low risk of death from rebound toxicity with heroin, but caution with polysubstance use and long-acting opioids [18][20]
Consult triggers
- Toxicology/Poison Control — refractory cases, unknown substances, body packing
- Psychiatry — intentional overdose
- Addiction medicine — initiation of medications for opioid use disorder
18. Follow Up / Return Precautions
- Prescribe naloxone to patient and close contacts at discharge [3][19]
- Return immediately for: recurrent drowsiness, difficulty breathing, chest pain, confusion, vomiting
- Follow-up within 1–3 days with primary care or addiction medicine for medication-assisted treatment initiation (buprenorphine, methadone) [3]
- Counsel on risk of fatal overdose after periods of abstinence due to loss of tolerance
- Expected recovery: patients who respond to naloxone and are observed without recurrence typically recover fully; however, toxic leukoencephalopathy can present days to weeks later [5-6]
- Harm reduction counseling: avoid using alone, use fentanyl test strips, start with small test doses, keep naloxone accessible [3]
The following decision algorithm from Boyer (NEJM) illustrates the management pathway for opioid analgesic overdose, including observation periods and disposition based on opioid formulation type:
References
1. Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Cao D, Arens AM, Chow SL, et al. Circulation. 2025.
2. Management of Opioid Analgesic Overdose. — Boyer EW. The New England Journal of Medicine. 2012.
3. Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose. — Harris MTH, Weinstein ZM, Walley AY. The Journal of the American Medical Association. 2026.
4. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Lavonas EJ, Akpunonu PD, Arens AM, et al. Circulation. 2023.
5. FDA Drug Label. — Updated date: 2026-01-14. Food and Drug Administration.
6. FDA Drug Label. — Updated date: 2026-01-31. Food and Drug Administration.
7. Mechanisms of Neurorespiratory Toxicity Induced by Fentanyl Analogs-Lessons From Animal Studies. — Chamoun K, Chevillard L, Hajj A, Callebert J, Mégarbane B. Pharmaceuticals. 2023.
8. Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis. — Torralva R, Janowsky A. The Journal of Pharmacology and Experimental Therapeutics. 2019.
9. FDA Drug Label. — Updated date: 2025-07-31. Food and Drug Administration.
10. FDA Drug Label. — Updated date: 2024-10-04. Food and Drug Administration.
11. Diagnostic and Statistical Manual of Mental Disorders. — Dilip V. Jeste, Jeffrey A. Lieberman, David Fassler, et al American Psychiatric Association (2022). 2022.
12. Toxicities of Opioid Analgesics: Respiratory Depression, Histamine Release, Hemodynamic Changes, Hypersensitivity, Serotonin Toxicity. — Baldo BA. Archives of Toxicology. 2021.
13. Acute Medication Poisoning. — Vega IL, Griswold MK, Laskey D. American Family Physician. 2024.
14. Evaluation of Machine-Learning Algorithms for Predicting Opioid Overdose Risk Among Medicare Beneficiaries With Opioid Prescriptions. — Lo-Ciganic WH, Huang JL, Zhang HH, et al. JAMA Network Open. 2019.
15. Practice-Based Guidelines: Buprenorphine in the Age of Fentanyl (PCSS Guidance). — American Academy of Addiction Psychiatry; American Society of Addiction Medicine (2023). 2023.
16. Abuse of Fentanyl: An Emerging Problem to Face. — Kuczyńska K, Grzonkowski P, Kacprzak Ł, Zawilska JB. Forensic Science International. 2018.
17. Toxin-Induced Coma and Central Nervous System Depression. — Krause M, Hocker S. Neurologic Clinics. 2020.
18. Opioid-Associated Out-of-Hospital Cardiac Arrest: Distinctive Clinical Features and Implications for Health Care and Public Responses: A Scientific Statement From the American Heart Association. — Dezfulian C, Orkin AM, Maron BA, et al. Circulation. 2021.
19. Naloxone and Buprenorphine Treatment for Adolescent Opioid Overdose and Opioid Use Disorder. — Ball A, Buresh C, Hadland SE. JAMA Pediatrics. 2026.
20. Do Heroin Overdose Patients Require Observation After Receiving Naloxone?. — Willman MW, Liss DB, Schwarz ES, Mullins ME. Clinical Toxicology. 2017.